Literature DB >> 29633146

Sequential clomiphene/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study.

Deirdre Zander-Fox1,2,3, Michelle Lane4,5,6, Hamish Hamilton4,5, Kelton Tremellen4,7.   

Abstract

PURPOSE: Mild controlled ovarian hyperstimulation (COH), combined with oocyte retrieval (OR) under local anaesthesia (LA), may provide low-impact IVF. Since a single injection of corifollitrophin alfa (CFA) provides 7 days of COH, we hypothesised that clomiphene-citrate (CC) followed by CFA may provide adequate COH response from one single FSH injection. Therefore, the aim was to assess IVF outcomes after a novel clomiphene citrate/CFA (CC/CFA) protocol, compared to women undergoing standard rFSH COH protocols (good prognosis comparative cohort:GPCC) in a 1:2 matched design.
MATERIALS AND METHODS: In this pilot study of 25 patients (ANZCTR id:ACTRN12612000740897, MINIVA:Minimal_Stimulation_in_IVF), we examined the effectiveness of oral clomiphene (100 mg-days 2-6) followed by CFA in a GnRH antagonist protocol producing a single injection COH stimulation regime. All OR were conducted under LA pre-ovarian block. Cycle outcomes were compared to a matched good prognosis comparative cohort (GPCC) undergoing standard rFSH COH.
RESULTS: Mild stimulation was achieved with less oocytes being collected compared to the GPCC (6.4 ± 0.7 vs. 10.7 ± 0.9, p < 0.001), resulting in a reduced number of good quality embryos available for transfer/cryopreservation (3.7 ± 0.6 vs. 5.7 ± 0.5, p = 0.01). While embryo quality was similar between the two groups, endometrial thickness was significantly lower in the group receiving CC/CFA. Pregnancy rates were significantly lower in the CC/CFA cohort compared to GPCC (31.8 vs. 57.1%, p = 0.04) and 44% of CC/CFA participants required supplemental rFSH in order to achieve the hCG trigger criteria.
CONCLUSION: Sequential clomiphene CFA protocol does not appear to be an optimal regime for low impact IVF treatment as it does not provide adequate COH from a single CFA injection and results in lower fresh embryo transfer pregnancy rates and fewer embryos for cryopreservation.

Entities:  

Keywords:  Clomiphene; Controlled ovarian hyperstimulation; Corifollitrophin alfa; IVF

Mesh:

Substances:

Year:  2018        PMID: 29633146      PMCID: PMC6030000          DOI: 10.1007/s10815-018-1172-y

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  20 in total

1.  Mild ovarian stimulation for IVF: 10 years later.

Authors:  Bart C J M Fauser; Geeta Nargund; Anders Nyboe Andersen; Robert Norman; Basil Tarlatzis; Jacky Boivin; William Ledger
Journal:  Hum Reprod       Date:  2010-09-21       Impact factor: 6.918

Review 2.  Slow freezing, vitrification and ultra-rapid freezing of human embryos: a systematic review and meta-analysis.

Authors:  Faten F AbdelHafez; Nina Desai; Ahmed M Abou-Setta; Tommaso Falcone; James Goldfarb
Journal:  Reprod Biomed Online       Date:  2009-11-27       Impact factor: 3.828

3.  Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women.

Authors: 
Journal:  Reprod Biomed Online       Date:  2010-03-28       Impact factor: 3.828

Review 4.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

5.  Pre-ovarian block versus paracervical block for oocyte retrieval.

Authors:  Anna Cerne; Christina Bergh; Kia Borg; Ingvar Ek; Ann-Louise Gejervall; Torbjörn Hillensjö; Jan I Olofsson; Elisabet Stener-Victorin; Margareta Wood; Göran Westlander
Journal:  Hum Reprod       Date:  2006-07-13       Impact factor: 6.918

6.  Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.

Authors:  Stamatina Iliodromiti; Christophe Blockeel; Kelton P Tremellen; Richard Fleming; Herman Tournaye; Peter Humaidan; Scott M Nelson
Journal:  Hum Reprod       Date:  2013-07-19       Impact factor: 6.918

7.  Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.

Authors:  R P Dickey; T T Olar; S N Taylor; D N Curole; E M Matulich
Journal:  Fertil Steril       Date:  1993-04       Impact factor: 7.329

Review 8.  The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.

Authors:  Adam H Balen; Lara C Morley; Marie Misso; Stephen Franks; Richard S Legro; Chandrika N Wijeyaratne; Elisabet Stener-Victorin; Bart C J M Fauser; Robert J Norman; Helena Teede
Journal:  Hum Reprod Update       Date:  2016-08-10       Impact factor: 15.610

9.  Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women.

Authors:  David J McLernon; Abha Maheshwari; Amanda J Lee; Siladitya Bhattacharya
Journal:  Hum Reprod       Date:  2016-01-18       Impact factor: 6.918

10.  A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.

Authors:  P Devroey; R Boostanfar; N P Koper; B M J L Mannaerts; P C Ijzerman-Boon; B C J M Fauser
Journal:  Hum Reprod       Date:  2009-08-14       Impact factor: 6.918

View more
  1 in total

1.  Corifollitropin alpha, clomiphene citrate and dydrogesterone without daily gonadotrophin: a new option of a friendly protocol for high-responder oocyte donors.

Authors:  Anderson Sanches de Melo; Camilla Teles Vidal de Paula; Thiago Lopes Dos Santos; Victor Antonio Costa Faria; Marcelo Augusto Feres Rufato; Rebecca Pontelo Barboza; Jorge Barreto
Journal:  JBRA Assist Reprod       Date:  2022-04-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.